Edwards Lifesciences Corp (EW)

Currency in USD
78.71
+0.61(+0.78%)
Closed·
80.12+1.41(+1.79%)
·
Earnings results expected tomorrow
EW is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
77.4478.89
52 wk Range
65.9487.89
Key Statistics
Prev. Close
78.71
Open
78.71
Day's Range
77.44-78.89
52 wk Range
65.94-87.89
Volume
6.48M
Average Vol. (3m)
3.48M
1-Year Change
11.8834%
Book Value / Share
17.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EW Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
97.11
Upside
+23.37%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Edwards Lifesciences Corp Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corp SWOT Analysis


Future Trajectory
Explore analysts' optimistic outlook, with price targets ranging from $83 to $95, as Edwards navigates challenges to achieve projected double-digit growth
Market Positioning
Delve into Edwards' competitive edge in cardiac devices, balancing high P/E ratio with innovation and stability in a fiercely contested market
TMTT Breakthrough
Rapid expansion in Transcatheter Mitral and Tricuspid Therapies segment emerges as a key growth driver, diversifying revenue streams
TAVR Dominance
Edwards Lifesciences' strong TAVR growth and potential NCD reopening signal promising future for its flagship product line, driving market leadership
Read full SWOT analysis

Edwards Lifesciences Corp Earnings Call Summary for Q3/2025

  • Edwards Lifesciences reported Q3 2025 adjusted EPS of $0.67 (13.56% above expectations) and revenue of $1.55 billion (up 12.6% YoY), despite a slight stock decline after hours.
  • The company raised its full-year sales growth guidance to the high end of 9-10% range and adjusted EPS guidance to between $2.56 and $2.62, targeting 10% organic growth in 2026.
  • Strong performance was driven by advancements in transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT), with TMTT sales expected to reach $530-550 million.
  • CEO Bernard Zovighian emphasized the company's leadership in the structural heart market, while CFO Scott Ullem highlighted R&D (18.1% of sales) as a strategic investment in top-line growth.
Last Updated: 10/30/2025, 06:32 PM
Read Full Transcript

Compare EW to Peers and Sector

Metrics to compare
EW
Peers
Sector
Relationship
P/E Ratio
34.0x22.2x−0.5x
PEG Ratio
−0.510.450.00
Price / Book
4.5x3.1x2.6x
Price / LTM Sales
7.8x2.5x3.3x
Upside (Analyst Target)
25.1%50.3%45.6%
Fair Value Upside
Unlock21.2%5.8%Unlock

Analyst Ratings

21 Buy
12 Hold
0 Sell
Ratings:
33 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 97.11
(+23.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Hold94.00+19.43%95.00MaintainFeb 04, 2026
Piper Sandler
Buy98.00+24.51%95.00MaintainJan 20, 2026
Stifel
Buy110.00+39.75%105.00MaintainJan 20, 2026
UBS
Hold95.00+20.70%92.00MaintainJan 12, 2026
Baird
Hold90.00+14.34%87.00MaintainJan 12, 2026

Earnings

Latest Release
Oct 30, 2025
EPS / Forecast
0.67 / 0.59
Revenue / Forecast
1.55B / 1.50B
EPS Revisions
Last 90 days

EW Income Statement

People Also Watch

271.63
RMD
+1.72%
76.27
BSX
-1.76%
282.58
WDC
+8.61%
69.97
DXCM
+0.11%
394.69
MU
+3.08%

FAQ

What Is the Edwards Lifesciences (EW) Stock Price Today?

The Edwards Lifesciences stock price today is 78.71

What Stock Exchange Does Edwards Lifesciences Trade On?

Edwards Lifesciences is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Edwards Lifesciences?

The stock symbol for Edwards Lifesciences is "EW."

What Is the Edwards Lifesciences Market Cap?

As of today, Edwards Lifesciences market cap is 45.68B.

What Is Edwards Lifesciences's Earnings Per Share (TTM)?

The Edwards Lifesciences EPS (TTM) is 2.29.

When Is the Next Edwards Lifesciences Earnings Date?

Edwards Lifesciences will release its next earnings report on Feb 10, 2026.

From a Technical Analysis Perspective, Is EW a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Edwards Lifesciences Stock Split?

Edwards Lifesciences has split 3 times.

How Many Employees Does Edwards Lifesciences Have?

Edwards Lifesciences has 15800 employees.

What is the current trading status of Edwards Lifesciences (EW)?

As of Feb 09, 2026, Edwards Lifesciences (EW) is trading at a price of 78.71, with a previous close of 78.71. The stock has fluctuated within a day range of 77.44 to 78.89, while its 52-week range spans from 65.94 to 87.89.

What Is Edwards Lifesciences (EW) Price Target According to Analysts?

The average 12-month price target for Edwards Lifesciences is USD97.11, with a high estimate of USD110 and a low estimate of USD84. 21 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +23.37% Upside potential.

What Is the EW After Hours Price?

EW's last after hours stock price is 80.12, the stock has decreased by 1.41, or 1.79%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.